Hormonal
Dual and triple receptor agonists (targeting GLP-1, GIP, and/or Glucagon) provide superior weight loss and glycemic control compared to selective GLP-1 receptor agonists alone.
Newer medications that target multiple hormones (GLP-1, GIP, and Glucagon) are more effective for weight loss and blood sugar control than older GLP-1 drugs alone. Drugs like tirzepatide and retatrutide have shown remarkable results, with some patients losing over 20% of their body weight. These are taken once a week and are considered a major advancement in treating obesity and diabetes.
Tirzepatide has demonstrated superior efficacy compared to GLP-1 RAs alone, achieving unprecedented reductions in HbA1c and body weight...
Why this rating
Supported by clinical trials (e.g., SURPASS) and phase 2 trials for retatrutide.
Source
New and Interesting Benefits with New Molecules in Obesity and Type 2 Diabetes
Fernando Grover Páez et al. · IntechOpen eBooks · 2026
DOI 10.5772/intechopen.1009256
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →